Urate-lowering treatment
搜索文档
Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress
Prnewswire· 2025-09-08 08:30
Accessibility StatementSkip Navigation SAN FRANCISCO and SUZHOU, China, Sept. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that the results of the Phase 2 clinical study of the xanthine oxidase inhibitor (XOI) tigulixostat (R&D code: IBI128) ...